NasdaqGM - Nasdaq Real Time Price ? USD Adicet Bio, Inc. (ACET) Follow Compare 0.9185 +0.0045 (+0.49%) As of 1:21 PM EST. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma REDWOOD CITY, Calif. & BOSTON, November 18, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the opening of enrollment for the Phase 1 clinical trial evaluating ADI-270 in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC). Business Wire ? 3 days ago ACET +0.49% Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases REDWOOD CITY, Calif. & BOSTON, November 18, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the first LN patient has been dosed in the Phase 1 clinical trial evaluating ADI-001 in autoimmune diseases. Business Wire ? 4 days ago ACET +0.49% Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans? There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... Simply Wall St. ? 4 days ago ACET +0.49% Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024 REDWOOD CITY, Calif. & BOSTON, November 16, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic, gamma delta T cell therapies for autoimmune diseases and cancer, today announced that clinical biomarker data from the ADI-001 Phase 1 GLEAN trial which demonstrates robust tissue homing, significant CAR T cell activation, and complete CD19+ B cell depletion in secondary lymphoid tissue will be featured in an oral session at ACR Converge Business Wire ? 6 days ago ACET +0.49% Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates REDWOOD CITY, Calif. & BOSTON, November 06, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2024. Business Wire ? 15 days ago ACET +0.49% Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024 REDWOOD CITY, Calif. & BOSTON, November 05, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral presentation at the upcoming American College of Rheumatology (ACR) Convergence 2024 meeting, taking place November 14-19, 2024, in Washington, D.C. Business Wire ? 17 days ago ACET +0.49% Adicet Bio to Participate in Upcoming Investor Conferences REDWOOD CITY, Calif. & BOSTON, November 01, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that company management will participate in three upcoming investor conferences in November. Business Wire ? 21 days ago ACET +0.49% Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif. & BOSTON, October 31, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on October 31, 2024. Business Wire ? 21 days ago ACET +0.49% Adicet Bio Advances FDA-Approved Autoimmune Therapy Trials Adicet Bio ( (ACET) ) has provided an update. Adicet Bio has received FDA clearance to expand its investigational new drug application, allowing the evaluation of ADI-001 in idiopathic inflammatory myopathy and stiff person syndrome as part of an ongoing Phase 1 trial. This development marks a significant step in Adicet’s efforts to tackle six autoimmune diseases using its gamma delta T cell therapies. Patient enrollment for these conditions is slated to begin in early 2025, with initial clinica TipRanks ? last month ACET +0.49% Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome REDWOOD CITY, Calif. & BOSTON, October 16, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has agreed to an amendment to the Company’s Investigational New Drug (IND) application to evaluate ADI-001 in idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS) as part of the ongoing Phase 1 Business Wire ? last month ACET +0.49% Adicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference REDWOOD CITY, Calif. & BOSTON, September 30, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral presentation at the upcoming American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene and Cell Therapies for Cancer conference, taking place October 16 – 17, 2024, in Philadelphia, PA. Business Wire ? last month ACET +0.49% Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases REDWOOD CITY, Calif. & BOSTON, September 30, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the opening of enrollment for the Phase 1 clinical trial evaluating ADI-001 in autoimmune diseases. Business Wire ? last month ACET +0.49% ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue REDWOOD CITY, Calif. & BOSTON, September 19, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced ADI-001 clinical biomarker data from the Phase 1 GLEAN trial which further reinforces the potential of ADI-001 as a best-in-class allogeneic cell therapy for autoimmune diseases. Notably, ADI-001 demonstrated robust tissue trafficking resulting in high level Business Wire ? 2 months ago ACET +0.49% Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference REDWOOD CITY, Calif. & BOSTON, August 27, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference being held from September 9-11, 2024 in New York. Business Wire ? 2 months ago ACET +0.49% Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors REDWOOD CITY, Calif. & BOSTON, August 19, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Lloyd Klickstein, M.D., Ph.D. to its Board of Directors. Business Wire ? 3 months ago ACET +0.49% Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates REDWOOD CITY, Calif. & BOSTON, August 13, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the second quarter ended June 30, 2024. Business Wire ? 3 months ago ACET +0.49% Why Is Adicet Bio, Inc. (ACET) a Good One-Dollar Stock to Buy According to Hedge Funds? We recently compiled a list of the 10 Best One-Dollar Stocks To Buy Now. In this article, we are going to take a look at where Adicet Bio, Inc. (NASDAQ:ACET) stands against the other one-dollar stocks. The upward trend in the stock market has resumed, supported by strong first-quarter and second-quarter results that have relieved […] Insider Monkey ? 3 months ago ACET +0.49% Owning 44% shares,institutional owners seem interested in Adicet Bio, Inc. (NASDAQ:ACET), Key Insights Given the large stake in the stock by institutions, Adicet Bio's stock price might be vulnerable to their... Simply Wall St. ? 3 months ago ACET +0.49% Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma REDWOOD CITY, Calif. & BOSTON, July 08, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-270 for the potential treatment of patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC) who have been treated with an immune checkpoint inhibitor and a vasc Business Wire ? 4 months ago ACET +0.49% Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma REDWOOD CITY, Calif. & BOSTON, June 24, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to evaluate ADI-270, an armored allogeneic "off-the-shelf" gamma delta chimeric antigen receptor (CAR) T cell therapy candidate targeting CD70+ c Business Wire ? 4 months ago ACET +0.49% Performance Overview Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return ACET S&P 500 YTD -51.40% +25.16% 1-Year -20.13% +31.55% 3-Year -90.13% +27.08%
